Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Alx Oncology Holdings (ALXO) Receivables - Other (2019 - 2020)

Alx Oncology Holdings' Receivables - Other history spans 2 years, with the latest figure at $500000.0 for Q3 2020.

  • On a quarterly basis, Receivables - Other changed N/A to $500000.0 in Q3 2020 year-over-year; TTM through Sep 2020 was $500000.0, a N/A change, with the full-year FY2019 number at $500000.0, changed N/A from a year prior.
  • Receivables - Other hit $500000.0 in Q3 2020 for Alx Oncology Holdings, roughly flat from $500000.0 in the prior quarter.
  • Over the last five years, Receivables - Other for ALXO hit a ceiling of $500000.0 in Q4 2019 and a floor of $500000.0 in Q4 2019.